[go: up one dir, main page]

NO20082445L - Neuropeptid-2 reseptor-agonister - Google Patents

Neuropeptid-2 reseptor-agonister

Info

Publication number
NO20082445L
NO20082445L NO20082445A NO20082445A NO20082445L NO 20082445 L NO20082445 L NO 20082445L NO 20082445 A NO20082445 A NO 20082445A NO 20082445 A NO20082445 A NO 20082445A NO 20082445 L NO20082445 L NO 20082445L
Authority
NO
Norway
Prior art keywords
neuropeptide
receptor agonists
obesity
diabetes
substituents
Prior art date
Application number
NO20082445A
Other languages
English (en)
Inventor
Waleed Danho
Joseph Swistok
Nader Fotouhi
David C Fry
Wajiha Khan
Karin Conde-Knape
George Ehrlich
Anish Konkar
Cristina Martha Rondinone
Rebecca Anne Taub
Jefferson Wright Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082445(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20082445L publication Critical patent/NO20082445L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det er tilveiebragt neuropeptid-2 reseptor-agonister med formel (I): Y' | Y-R1-R2-X-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-NH2 (I), så vel som farmasøytisk akseptable salter, derivater og fragmenter derav, hvor substituentene er som de beskrevet i beskrivelsen. Disse forbindelser og de farmasøytiske preparater inneholdende dem, er anvendelige for behandling av sykdommer så som for eksempel fedme og diabetes.
NO20082445A 2005-12-07 2008-05-28 Neuropeptid-2 reseptor-agonister NO20082445L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74807105P 2005-12-07 2005-12-07
US85524906P 2006-10-30 2006-10-30
PCT/EP2006/068924 WO2007065808A2 (en) 2005-12-07 2006-11-27 Neuropeptide-2 receptor-agonists

Publications (1)

Publication Number Publication Date
NO20082445L true NO20082445L (no) 2008-09-03

Family

ID=37964711

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082445A NO20082445L (no) 2005-12-07 2008-05-28 Neuropeptid-2 reseptor-agonister

Country Status (18)

Country Link
US (2) US7642244B2 (no)
EP (1) EP1962959B1 (no)
JP (1) JP5000663B2 (no)
KR (1) KR101059602B1 (no)
AR (1) AR057222A1 (no)
AT (1) ATE549350T1 (no)
AU (1) AU2006324076A1 (no)
BR (1) BRPI0619573A2 (no)
CA (1) CA2630649A1 (no)
EC (1) ECSP088511A (no)
ES (1) ES2381497T3 (no)
IL (1) IL191636A (no)
MA (1) MA30142B1 (no)
NO (1) NO20082445L (no)
NZ (1) NZ568772A (no)
RU (2) RU2430108C2 (no)
TW (1) TWI321474B (no)
WO (1) WO2007065808A2 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010069242A (ko) * 2000-09-05 2001-07-25 양우용 저주파 물리치료 겸용 혈압 강하기
BRPI0619573A2 (pt) * 2005-12-07 2011-10-04 Hoffmann La Roche agonista receptor de neuropeptìdeo-2, formulações farmacêuticas, uso de agonista receptor de neuropeptìdeo-2 e método de tratamento de uma doença modulada por agonistas receptores de neuropeptìdeos-2
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
CN102202681A (zh) * 2008-11-05 2011-09-28 霍夫曼-拉罗奇有限公司 神经肽-2受体(y-2r)激动剂及其用途
EP2450374B9 (en) 2009-07-02 2016-11-23 Takeda Pharmaceutical Company Limited Peptide and use thereof
CN102573888A (zh) * 2009-09-18 2012-07-11 诺和诺德公司 长效y2 受体激动剂
CN102596228A (zh) * 2009-10-13 2012-07-18 霍夫曼-拉罗奇有限公司 神经肽-2受体(y-2r)激动剂
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
CN103282054A (zh) * 2011-01-03 2013-09-04 弗·哈夫曼-拉罗切有限公司 抗dig抗体和与肽缀合的地高辛配基的复合物的药物组合物
LT2827885T (lt) 2012-03-22 2018-10-10 Novo Nordisk A/S Glp-1 peptidų kompozicijos ir jų gavimas
DK2869848T3 (en) 2012-07-04 2016-11-21 Hoffmann La Roche Covalent BOUND ANTIGEN-ANTIBODY CONJUGATES
MX354303B (es) 2012-07-04 2018-02-23 Hoffmann La Roche Anticuerpos de anti-biotina y metodos de uso.
ES2600154T3 (es) 2012-07-04 2017-02-07 F. Hoffmann-La Roche Ag Anticuerpos antiteofilina y métodos de uso
JP6672140B2 (ja) 2013-05-02 2020-03-25 ノヴォ ノルディスク アー／エス Ｇｌｐ−１化合物の経口投薬
CN105764919B (zh) 2013-11-15 2021-04-27 诺和诺德股份有限公司 在位置35具有β-高精氨酸置换的hPYY(1-36)
CN105722526B (zh) 2013-11-15 2020-12-08 诺和诺德股份有限公司 选择性pyy化合物及其用途
CA2930046A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked polypeptide toxin-antibody conjugates
EP3089758B1 (en) 2014-01-03 2021-01-27 F.Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
JP6476194B2 (ja) 2014-01-03 2019-02-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重特異性抗ハプテン／抗血液脳関門受容体抗体、それらの複合体、及び血液脳関門シャトルとしてのそれらの使用
MA41898A (fr) * 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CN107849110B (zh) 2015-06-12 2021-11-26 诺和诺德股份有限公司 选择性pyy化合物及其用途
MX2020007598A (es) 2018-02-02 2020-09-03 Novo Nordisk As Composiciones solidas que comprenden un agonista del peptido similar al glucagon tipo 1 (glp-1), una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante.
MX2022005661A (es) 2019-11-11 2022-09-07 Boehringer Ingelheim Int Agonistas del receptor npy2.
AU2021322137A1 (en) 2020-08-07 2023-01-19 Boehringer Ingelheim International Gmbh Soluble NPY2 receptor agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
NZ265452A (en) * 1993-03-29 1997-09-22 Univ Cincinnati Analogues of peptide yy, dimers and pharmaceutical compositions
AUPO029096A0 (en) 1996-06-05 1996-07-04 Crc For Biopharmaceutical Research Pty Ltd Npy y2 agonists
US6013633A (en) 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
AR030676A1 (es) * 1999-07-28 2003-09-03 Ortho Mcneil Pharm Inc Derivados de aminas y amidas como ligandos para el receptor del neuropeptido y y5 utiles en el tratamiento de la obesidad y otros trastornos, uso de los mismos para la elaboracion de medicamentos y composiciones farmaceuticas que los comprenden
US7811989B2 (en) 2003-01-17 2010-10-12 Ipsen Pharma S.A.S. Peptide YY analogs
PL1620118T3 (pl) 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
EP1689421A4 (en) 2003-11-25 2009-06-24 Bayer Healthcare Ag SELECTIVE AGONISTS OF NEUROPEPTIDE Y2 RECEPTOR
EP1718671A2 (en) 2004-02-23 2006-11-08 Rheoscience A/S Peptide yy analogues
US7410949B2 (en) * 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
WO2006091505A2 (en) 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Neuropeptide y receptor agonists
BRPI0619573A2 (pt) * 2005-12-07 2011-10-04 Hoffmann La Roche agonista receptor de neuropeptìdeo-2, formulações farmacêuticas, uso de agonista receptor de neuropeptìdeo-2 e método de tratamento de uma doença modulada por agonistas receptores de neuropeptìdeos-2
WO2007085887A1 (en) 2006-01-27 2007-08-02 Pfizer Products Inc. Pyy agonists and uses thereof

Also Published As

Publication number Publication date
JP5000663B2 (ja) 2012-08-15
RU2008127265A (ru) 2010-01-20
TWI321474B (en) 2010-03-11
US8268784B2 (en) 2012-09-18
ATE549350T1 (de) 2012-03-15
JP2009518349A (ja) 2009-05-07
RU2430108C2 (ru) 2011-09-27
TW200806311A (en) 2008-02-01
US7642244B2 (en) 2010-01-05
IL191636A0 (en) 2008-12-29
US20070135351A1 (en) 2007-06-14
IL191636A (en) 2012-10-31
ECSP088511A (es) 2008-07-30
CA2630649A1 (en) 2007-06-14
AR057222A1 (es) 2007-11-21
RU2011105310A (ru) 2012-08-20
EP1962959B1 (en) 2012-03-14
WO2007065808A2 (en) 2007-06-14
KR20080082672A (ko) 2008-09-11
KR101059602B1 (ko) 2011-08-25
BRPI0619573A2 (pt) 2011-10-04
NZ568772A (en) 2010-05-28
ES2381497T3 (es) 2012-05-28
EP1962959A2 (en) 2008-09-03
MA30142B1 (fr) 2009-01-02
WO2007065808A3 (en) 2007-08-02
US20100137223A1 (en) 2010-06-03
AU2006324076A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
NO20082445L (no) Neuropeptid-2 reseptor-agonister
NO20073664L (no) Peptider med neuropeptid-2-reseptor (Y2R) agonist aktivitet
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
NO20074872L (no) Pyrazoler
NO20092033L (no) Nye forbindelser
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
NO20070176L (no) Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
NO20074703L (no) Antibakterielle piperidinderivater
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
TW200621762A (en) Novel compounds
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
NO20066055L (no) Pyridinderivater
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
WO2007128480A3 (en) Thioglycosides as pharmaceutically active agents
WO2007087548A3 (en) Chemical compounds
NO20084049L (no) Forbindelser med forsterket ampa receptor og anvendelse derav i medisin
NO20082496L (no) Pyrazinderivater
NO20081844L (no) Terapeutiske forbindelser
NO20065904L (no) Terapeutiske forbindelser
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
IN2012DN03042A (no)
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application